BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1633400)

  • 21. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
    J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
    Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
    J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage activity in infected areas of an experimental vertebral osteomyelitis model: USPIO-enhanced MR imaging--feasibility study.
    Bierry G; Jehl F; Boehm N; Robert P; Prévost G; Dietemann JL; Desal H; Kremer S
    Radiology; 2008 Jul; 248(1):114-23. PubMed ID: 18458246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans.
    Mitchell DG; Kim I; Chang TS; Vinitski S; Consigny PM; Saponaro SA; Ehrlich SM; Rifkin MD; Rubin R
    Invest Radiol; 1991 Dec; 26(12):1041-52. PubMed ID: 1765436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats.
    Okada M; Katsube T; Kumano S; Kagawa Y; Araki T; Tsuda N; Okuaki T; Imaoka I; Tanigawa N; Ishii K; Murakami T
    Acta Radiol; 2011 Jul; 52(6):658-64. PubMed ID: 21498305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
    del Frate C; Bazzocchi M; Mortele KJ; Zuiani C; Londero V; Como G; Zanardi R; Ros PR
    Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.
    Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M
    Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents.
    Kruskal JB; Lunderquist A; Clouse ME
    Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279
    [No Abstract]   [Full Text] [Related]  

  • 31. T2-weighted and T1-weighted dynamic superparamagnetic iron oxide (ferucarbotran) enhanced MRI of hepatocellular carcinoma and hyperplastic nodules.
    Chen RC; Lii JM; Chou CT; Chang TA; Chen WT; Li CS; Tu HY
    J Formos Med Assoc; 2008 Oct; 107(10):798-805. PubMed ID: 18926947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity.
    Tanabe M; Ito K; Shimizu A; Fujita T; Onoda H; Yamatogi S; Washida Y; Matsunaga N
    Magn Reson Imaging; 2009 Jul; 27(6):801-6. PubMed ID: 19144487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
    Lee JM; Kim CS; Youk JH; Lee MS
    Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging.
    Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ
    Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging.
    Kim SK; Kim SH; Lee WJ; Kim H; Seo JW; Choi D; Lim HK; Lee SJ; Lim JH
    AJR Am J Roentgenol; 2002 Sep; 179(3):741-50. PubMed ID: 12185056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.